Literature DB >> 21740995

The role of platelet factor 4 in radiation-induced thrombocytopenia.

Michele P Lambert1, Liqing Xiao, Yvonne Nguyen, M Anna Kowalska, Mortimer Poncz.   

Abstract

PURPOSE: Factors affecting the severity of radiation-induced thrombocytopenia (RIT) are not well described. We address whether platelet factor 4 (PF4; a negative paracrine for megakaryopoiesis) affects platelet recovery postradiation. METHODS AND MATERIALS: Using conditioned media from irradiated bone marrow (BM) cells from transgenic mice overexpressing human (h) PF4 (hPF4+), megakaryocyte colony formation was assessed in the presence of this conditioned media and PF4 blocking agents. In a model of radiation-induced thrombocytopenia, irradiated mice with varying PF4 expression levels were treated with anti-hPF4 and/or thrombopoietin (TPO), and platelet count recovery and survival were examined.
RESULTS: Conditioned media from irradiated BM from hPF4+ mice inhibited megakaryocyte colony formation, suggesting that PF4 is a negative paracrine released in RIT. Blocking with an anti-hPF4 antibody restored colony formation of BM grown in the presence of hPF4+ irradiated media, as did antibodies that block the megakaryocyte receptor for PF4, low-density lipoprotein receptor-related protein 1 (LRP1). Irradiated PF4 knockout mice had higher nadir platelet counts than irradiated hPF4+/knockout litter mates (651 vs. 328 × 106/mcL, p = 0.02) and recovered earlier (15 days vs. 22 days, respectively, p <0.02). When irradiated hPF4+ mice were treated with anti-hPF4 antibody and/or TPO, they showed less severe thrombocytopenia than untreated mice, with improved survival and time to platelet recovery, but no additive effect was seen.
CONCLUSIONS: Our studies show that in RIT, damaged megakaryocytes release PF4 locally, inhibiting platelet recovery. Blocking PF4 enhances recovery while released PF4 from megakaryocytes limits TPO efficacy, potentially because of increased release of PF4 stimulated by TPO. The clinical value of blocking this negative paracrine pathway post-RIT remains to be determined.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21740995      PMCID: PMC3134787          DOI: 10.1016/j.ijrobp.2011.03.039

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  29 in total

Review 1.  Major radiation exposure--what to expect and how to respond.

Authors:  Fred A Mettler; George L Voelz
Journal:  N Engl J Med       Date:  2002-05-16       Impact factor: 91.245

2.  Ultrastructural study shows morphologic features of apoptosis and para-apoptosis in megakaryocytes from patients with idiopathic thrombocytopenic purpura.

Authors:  Ewout J Houwerzijl; Nel R Blom; Johannes J L van der Want; Mariet T Esselink; Jan J Koornstra; Jan W Smit; Henk Louwes; Edo Vellenga; Joost Th M de Wolf
Journal:  Blood       Date:  2003-09-11       Impact factor: 22.113

Review 3.  Recombinant human thrombopoietin: basic biology and evaluation of clinical studies.

Authors:  David J Kuter; C Glenn Begley
Journal:  Blood       Date:  2002-11-15       Impact factor: 22.113

4.  Recombinant human interleukin-11 synergizes with steel factor and interleukin-3 to promote directly the early stages of murine megakaryocyte development in vitro.

Authors:  N S Weich; M Fitzgerald; A Wang; J Calvetti; J Yetz-Aldape; S Neben; K J Turner
Journal:  Blood       Date:  2000-01-15       Impact factor: 22.113

5.  Localization of distal regulatory domains in the megakaryocyte-specific platelet basic protein/platelet factor 4 gene locus.

Authors:  C Zhang; M A Thornton; M A Kowalska; B S Sachis; M Feldman; M Poncz; S E McKenzie; M P Reilly
Journal:  Blood       Date:  2001-08-01       Impact factor: 22.113

6.  Interleukin-6 stimulates thrombopoiesis through thrombopoietin: role in inflammatory thrombocytosis.

Authors:  A Kaser; G Brandacher; W Steurer; S Kaser; F A Offner; H Zoller; I Theurl; W Widder; C Molnar; O Ludwiczek; M B Atkins; J W Mier; H Tilg
Journal:  Blood       Date:  2001-11-01       Impact factor: 22.113

7.  Numerous growth factors, cytokines, and chemokines are secreted by human CD34(+) cells, myeloblasts, erythroblasts, and megakaryoblasts and regulate normal hematopoiesis in an autocrine/paracrine manner.

Authors:  M Majka; A Janowska-Wieczorek; J Ratajczak; K Ehrenman; Z Pietrzkowski; M A Kowalska; A M Gewirtz; S G Emerson; M Z Ratajczak
Journal:  Blood       Date:  2001-05-15       Impact factor: 22.113

Review 8.  Role of the platelet chemokine platelet factor 4 (PF4) in hemostasis and thrombosis.

Authors:  M Anna Kowalska; Lubica Rauova; Mortimer Poncz
Journal:  Thromb Res       Date:  2009-12-09       Impact factor: 3.944

9.  Binding of platelet factor 4 to heparin oligosaccharides.

Authors:  J Denton; D A Lane; L Thunberg; A M Slater; U Lindahl
Journal:  Biochem J       Date:  1983-02-01       Impact factor: 3.857

Review 10.  Hematologic consequences of exposure to ionizing radiation.

Authors:  Nicholas Dainiak
Journal:  Exp Hematol       Date:  2002-06       Impact factor: 3.084

View more
  8 in total

1.  Platelet factor 4 protects bone marrow mesenchymal stem cells from acute radiation injury.

Authors:  J-J Chen; Y Gao; Q Tian; Y-M Liang; L Yang
Journal:  Br J Radiol       Date:  2014-06-12       Impact factor: 3.039

2.  Platelet factor 4 increases bone marrow B cell development and differentiation.

Authors:  David J Field; Angela A Aggrey-Amable; Sara K Blick; Sara K Ture; Andrew Johanson; Scott J Cameron; Sukanya Roy; Craig N Morrell
Journal:  Immunol Res       Date:  2017-10       Impact factor: 2.829

3.  2-O, 3-O desulfated heparin mitigates murine chemotherapy- and radiation-induced thrombocytopenia.

Authors:  Elizabeth Tkaczynski; Abinaya Arulselvan; John Tkaczynski; Stephen Avery; Liqing Xiao; Beverly Torok-Storb; Kraig Abrams; Narayanam V Rao; Gregory Johnson; Thomas P Kennedy; Mortimer Poncz; Michele P Lambert
Journal:  Blood Adv       Date:  2018-04-10

4.  Expansion of Human Megakaryocyte-Lineage Progeny via Aryl Hydrocarbon Receptor Antagonism with CH223191.

Authors:  Dongchan Kim; Dong-Yeop Shin; Jun Liu; Na-Rae Jeong; Youngil Koh; Junshik Hong; Xinxin Huang; Hal E Broxmeyer; Sung-Soo Yoon
Journal:  Stem Cell Rev Rep       Date:  2022-06-10       Impact factor: 5.739

5.  Intramedullary megakaryocytes internalize released platelet factor 4 and store it in alpha granules.

Authors:  M P Lambert; R Meng; L Xiao; D C Harper; M S Marks; M A Kowalska; M Poncz
Journal:  J Thromb Haemost       Date:  2015-09-29       Impact factor: 5.824

6.  Monitoring of platelet function parameters and microRNA expression levels in patients with prostate cancer treated with volumetric modulated arc radiotherapy.

Authors:  Nurten Bahtiyar; İlhan Onaran; Birsen Aydemir; Onur Baykara; Selmin Toplan; Fulya Yaman Agaoglu; Mehmet Can Akyolcu
Journal:  Oncol Lett       Date:  2018-07-18       Impact factor: 2.967

7.  Platelet factor 4 platelet levels are inversely correlated with steady-state platelet counts and with platelet transfusion needs in pediatric leukemia patients.

Authors:  M P Lambert; A Reznikov; A Grubbs; Y Nguyen; L Xiao; R Aplenc; L Rauova; M Poncz
Journal:  J Thromb Haemost       Date:  2012-07       Impact factor: 5.824

Review 8.  Role of platelet chemokines, PF-4 and CTAP-III, in cancer biology.

Authors:  Katerina Pilatova; Kristina Greplova; Regina Demlova; Beatrix Bencsikova; Giannoula Lakka Klement; Lenka Zdrazilova-Dubska
Journal:  J Hematol Oncol       Date:  2013-06-24       Impact factor: 17.388

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.